Improved angiogenic potency by implantation of ex vivo hypoxia prestimulated bone marrow cells in rats.
Therapeutic angiogenesis can be induced by local implantation of bone marrow cells. We tried to enhance the angiogenic potential of this treatment by ex vivo hypoxia stimulation of bone marrow cells before implantation. Bone marrow cells were collected and cultured at 33 degrees C under 2% O(2)-5% CO(2)-90% N(2) (hypoxia) or 95% air-5% CO(2) (normoxia). Cells were also injected into the ischemic hindlimb of rats after 24 h of culture. Hypoxia culture increased the mRNA expression of vascular endothelial growth factor (VEGF), vascular endothelial (VE)-cadherin, and fetal liver kinase-1 (Flk-1) from 2.5- to fivefold in bone marrow cells. The levels of VEGF protein in the ischemic hindlimb were significantly higher 1 and 3 days after implantation with hypoxia-cultured cells than with normoxia-cultured or noncultured cells. The microvessel density and blood flow rate in the ischemic hindlimbs were also significantly (P < 0.001) higher 2 wk after implantation with hypoxia-cultured cells (89.7 +/- 5.5%) than with normoxia-cultured cells (67.0 +/- 9.6%) or noncultured cells (70.4 +/- 7.7%). Ex vivo hypoxia stimulation increased the VEGF mRNA expression and endothelial differentiation of bone marrow cells, which together contributed to improved therapeutic angiogenesis in the ischemic hindlimb after implantation.
Li
Tao-Sheng
TS
Department of Bioregulation, Yamaguchi University School of Medicine, 1-1-1 Monami-Kogushi, Ube, Yamaguchi, Japan 755-8505.
Hamano
Kimikazu
K
Suzuki
Kazuhiko
K
Ito
Hiroshi
H
Zempo
Nobuya
N
Matsuzaki
Masunori
M
D000818:Animals; D015703:Antigens, CD; D001808:Blood Vessels / Q000473:pathology; D001854:Bone Marrow Cells / Q000378:metabolism; D016026:Bone Marrow Transplantation; D015820:Cadherins / Q000235:genetics; D015687:Cell Hypoxia / Q000502:physiology*; D002478:Cells, Cultured; D016228:Endothelial Growth Factors / Q000235:genetics; D006614:Hindlimb / Q000098:blood supply*; D007511:Ischemia / Q000473:pathology / Q000503:physiopathology* / Q000601:surgery*; D008222:Lymphokines / Q000235:genetics; D008297:Male; D008833:Microcirculation; D018919:Neovascularization, Physiologic; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D017978:Receptors, Growth Factor / Q000235:genetics; D040262:Receptors, Vascular Endothelial Growth Factor; D012039:Regional Blood Flow; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000099152:Cadherin 5
D015703:Antigens, CD; D015820:Cadherins; D016228:Endothelial Growth Factors; D008222:Lymphokines; D012333:RNA, Messenger; D020794:Receptor Protein-Tyrosine Kinases; D017978:Receptors, Growth Factor; D040262:Receptors, Vascular Endothelial Growth Factor; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000099152:Cadherin 5